lapatinib has been researched along with Ovarian Neoplasms in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bindhya, S; Ganesan, TS; Joshua, T; Krishnapriya, S; Manasa, P; Murhekar, K; Nagare, RP; Shabna, A; Sidhanth, C; Sneha, S | 1 |
| Alifia, J; Bindhya, S; Ganesan, TS; Garg, M; Krishnapriya, S; Kumar, V; Manasa, P; Patole, C; Shabna, A; Sidhanth, C | 1 |
| Chaluvally-Raghavan, P; Geethadevi, A; George, J; Gopinadhan Nair, GK; Kadamberi, IP; Lu, Y; Mills, GB; Nair, A; Nair, B; Parashar, D; Pradeep, S; Rader, JS; Ram, PT; Ramchandran, R; Tsaih, SW; Uyar, DS | 1 |
| Gorski, JW; Kolesar, JM; Lin, N; Liu, J; McCorkle, JR; McDowell, AB; Riggs, MB; Ueland, FR; Wang, C | 1 |
| Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E | 1 |
| Li, B; Li, Y; Liu, Z; Shu, T; Wu, X | 1 |
| Bown, JL; Deeni, YY; Kankia, IH; Khalil, HS; Langdon, SP; Moult, PR | 1 |
| Ambartsumian, N; Andersen, SH; Brix, DM; Bundgaard Clemmensen, K; Jäättelä, M; Kallunki, T; Rafn, B | 1 |
| Muggia, F; Teplinsky, E | 1 |
| Bai, Y; Black, J; Carvajal-Hausdorf, DE; Rimm, DL; Santin, AD; Schalper, KA | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Alvarez, RD; Barnes, MN; Estes, JM; Kimball, KJ; Kirby, TO; Koch, KM; Matei, DE; Numnum, TM; Zamboni, WC | 1 |
| Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL | 1 |
| Albini, A; Anzà, C; Baravelli, M; Bucci, EO; Cammarota, R; Cesana, E; Donatelli, F; Noonan, DM | 1 |
| Anees, M; Dolznig, H; El-Gazzar, A; Grunt, TW; Holcmann, M; Horak, P; Horvat, R; Krainer, M; Pils, D; Savarese-Brenner, B; Schemper, M; Schöfer, C; Sibilia, M; Vanhara, P; Wittinger, M; Zeillinger, R | 1 |
| Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM | 1 |
| Bellomo, C; Leporatti, S; Lorusso, V; Lvov, YM; Maffia, M; Rinaldi, R; Tinelli, A; Vergara, D; Vergaro, V; Zhang, X | 1 |
| Ji, Y; Lu, Y; Mills, GB; Müller, P; Nieto-Barajas, LE | 1 |
| Bezler, M; Hengstler, JG; Ullrich, A | 1 |
| Jain, A; Ryan, PD; Seiden, MV | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Harada, T; Itamochi, H; Kato, M; Kigawa, J; Kudoh, A; Naniwa, J; Nishimura, M; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N | 1 |
| Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L | 1 |
| Brose, MS; Flaherty, KT | 1 |
2 review(s) available for lapatinib and Ovarian Neoplasms
| Article | Year |
|---|---|
Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Topics: Adenocarcinoma, Mucinous; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Ovarian Neoplasms; Quinazolines; Trastuzumab; Uterine Neoplasms | 2014 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
5 trial(s) available for lapatinib and Ovarian Neoplasms
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2008 |
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan | 2011 |
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines | 2012 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
17 other study(ies) available for lapatinib and Ovarian Neoplasms
| Article | Year |
|---|---|
LASP-1 interacts with ErbB2 in ovarian cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adult; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Cytoskeletal Proteins; Female; HEK293 Cells; Humans; Lapatinib; LIM Domain Proteins; Middle Aged; Ovarian Neoplasms; Phosphorylation; Plasmids; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2022 |
Phosphoproteome of signaling by ErbB2 in ovarian cancer cells.
Topics: Aldehyde Reductase; Cell Line, Tumor; Epidermal Growth Factor; Female; Humans; Lapatinib; Ovarian Neoplasms; Phosphoproteins; Receptor, ErbB-2 | 2022 |
Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; ErbB Receptors; Female; Forkhead Box Protein M1; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Ovarian Neoplasms; Peritoneal Neoplasms; Receptor, ErbB-2; Signal Transduction; Thiostrepton; Transfection | 2020 |
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Proteins; Ovarian Neoplasms; Quinazolines | 2021 |
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cystadenocarcinoma, Serous; Down-Regulation; Female; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Middle Aged; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Ubiquitin-Protein Ligases | 2017 |
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; MCF-7 Cells; NF-E2-Related Factor 2; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrahydronaphthalenes | 2017 |
Screening and identification of small molecule inhibitors of ErbB2-induced invasion.
Topics: Antineoplastic Agents; Cathepsin L; Female; Humans; Lapatinib; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Extracellular Space; Female; Fluorescent Antibody Technique; Humans; Intracellular Space; Lapatinib; Maytansine; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Protein Domains; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Tissue Array Analysis; Trastuzumab; Uterine Neoplasms | 2017 |
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heart; Humans; Lapatinib; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Razoxane; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cetuximab; Endosomal Sorting Complexes Required for Transport; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Ovarian Neoplasms; Prognosis; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2011 |
Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colloids; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Nanocapsules; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2012 |
A time-series DDP for functional proteomics profiles.
Topics: Bayes Theorem; Biomarkers, Tumor; Biometry; Cell Line, Tumor; Data Interpretation, Statistical; ErbB Receptors; Female; Humans; Lapatinib; Linear Models; Markov Chains; Models, Statistical; Monte Carlo Method; Multivariate Analysis; Ovarian Neoplasms; Protein Array Analysis; Proteomics; Quinazolines; Signal Transduction; Statistics, Nonparametric | 2012 |
Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Topics: ADAM Proteins; ADAM17 Protein; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cetuximab; Doxorubicin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Ovarian Neoplasms; Ovary; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2012 |
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cystadenocarcinoma, Mucinous; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.
Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Cytological Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |